ABX464 50mg

DRUG2 trials

Sponsors

Abivax S.A.

Conditions

HIV InfectionsHealth VolunteersRheumatoid Arthritis

Phase 1

A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

CompletedNCT02990325

Abivax S.A.Health Volunteers, HIV Infections

Start: 2017-03-27End: 2019-10-21Updated: 2023-03-31

Phase 2

Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

CompletedNCT03813199

Abivax S.A.Rheumatoid Arthritis

Start: 2019-07-04End: 2021-04-27Updated: 2023-02-15

Related Papers

Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

Annals of the Rheumatic Diseases2022-05-3128 citations

ABX464 Decreases the Total Human Immunodeficiency Virus (HIV) Reservoir and HIV Transcription Initiation in CD4+ T Cells From Antiretroviral Therapy–Suppressed Individuals Living With HIV

Clinical Infectious Diseases2021-08-2613 citations